title: [Mildronate effects on oxidant stress in type 2 diabetic patients with diabetic peripheral (sensomotor) neuropathy].
abstract: OBJECTIVE
  To clarify mildronate effects on oxidant stress and tissue oxygen in combined treatment of peripheral (sensomotor) neuropathy in patients with type 2 diabetes mellitus (DM).
  
  
  METHODS
  An open randomized trial investigated 70 matched patients with type 2 DM and sensomotor neuropathy. They were randomized into two groups. The study group received basic anti-diabetic treatment, alpha-lipoic acid and mildronate for 3 months. Patients of the control group received the same treatment but mildronate.
  
  
  RESULTS
  Mildronate administration improved clinical condition of the study group patients vs controls by neuropathy and symptoms count scales, electrophysiological properties of the nerve fibers, optimization of oxygen tissue balance, reduced production of lipid peroxidation products and activated enzymes of antioxidant defense.
  
  
  CONCLUSIONS
  It is recommended to add 1 g/day mildronate to standard schemes of treatment for diabetes and sensomotor neuropathy.
authors.forename: M E
authors.initials: ME
authors.lastname: Statsenko
authors.forename: L V
authors.initials: LV
authors.lastname: Poletaeva
authors.forename: S V
authors.initials: SV
authors.lastname: Turkina
authors.forename: A F
authors.initials: AF
authors.lastname: Apukhtin
authors.forename: G P
authors.initials: GP
authors.lastname: Dudchenko
mesh_terms: D000368:Aged; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology*; D003929:Diabetic Neuropathies / Q000453:epidemiology*; D005215:Fasting; D005260:Female; D006801:Humans; D008297:Male; D008763:Methylhydrazines / Q000627:therapeutic use*; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects*
chemical_list: D002317:Cardiovascular Agents; D008763:Methylhydrazines; C050147:3-(2,2,2-trimethylhydrazine)propionate